Hidden Gems - Unlocking Value in Biotech's Most Overlooked Stocks

On the latest WTR Healthcare Happenings podcast, we were joined by David Sans, PhD, a healthcare investment banker, and our host, Tim Gerdeman, WTR’s Vice-Chair, Co-Founder, and Chief Marketing Officer. Over the past two years, Sans has focused on a corner of the market most investors overlook: publicly listed companies with low or negative shareholders’ equity and stock prices trading below $1. The conversation covered the tightening Nasdaq listing environment, the mechanics of strategic asset acquisitions and structured financing, the shift in M&A toward asset-level transactions, and a compelling new instrument—clinical trial insurance—that is opening the door to a new class of biotech investors.